Ernexa Therapeutics Q3 operating loss down 44% YoY, ERNA-101 progress.
ByAinvest
Monday, Nov 10, 2025 8:41 am ET1min read
ERNA--
• Ernexa Therapeutics Q3 operating loss down 44% YoY • ERNA-101 lead program progresses toward Phase 1 study in ovarian cancer • Clinical trials anticipated in H2 2026 • Manufacturing partnership to advance ERNA-101 • Positive data presented at ASCO-2025 and AACR-2025 meetings
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet